Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma
- Conditions
- Persistent Asthma
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 758
- Registration Number
- NCT02175771
- Locations
- 🇺🇸
Teva Investigational Site 12146, Riverside, California, United States
🇺🇸Teva Investigational Site 12121, Dallas, Texas, United States
🇺🇸Teva Investigational Site 12124, Baltimore, Maryland, United States
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
- Conditions
- Asthma
- Interventions
- Drug: FS MDPIDrug: Fp MDPIDrug: Placebo MDPIDrug: Albuterol/salmeterol HFA MDI
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 882
- Registration Number
- NCT02141854
- Locations
- 🇭🇺
Teva Investigational Site 51150, Nyíregyháza, Hungary
🇭🇺Teva Investigational Site 51146, Szeged, Hungary
🇭🇺Teva Investigational Site 51151, Nyíregyháza, Hungary
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
- Conditions
- Asthma
- Interventions
- Drug: FS MDPIDrug: Fp MDPIDrug: Placebo MDPIDrug: albuterol/salbutamol
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 787
- Registration Number
- NCT02139644
- Locations
- 🇺🇸
Teva Investigational Site 12584, Longmont, Colorado, United States
🇺🇸Teva Investigational Site 12379, Centennial, Colorado, United States
🇺🇸Teva Investigational Site 12586, Fountain Valley, California, United States
A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT02126839
- Locations
- 🇺🇸
Teva Investigational Site 12510, Riverside, California, United States
🇺🇸Teva Investigational Site 12526, Miami, Florida, United States
🇺🇸Teva Investigational Site 12525, Cleveland, Ohio, United States
A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT02092571
- Locations
- 🇺🇸
Teva Investigational Site 12355, Miami, Florida, United States
A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together
- Conditions
- PharmacokineticsPharmacodynamics
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02085863
- Locations
- 🇩🇪
Teva Investigational Site 32415, Moenchengladbach, Germany
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02078960
- Locations
- 🇺🇸
Teva Investigational Site 12545, Jacksonville, Florida, United States
🇺🇸Teva Investigational Site 12550, Atlanta, Georgia, United States
🇺🇸Teva Investigational Site 12543, Indianapolis, Indiana, United States
A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 389
- Registration Number
- NCT02068599
- Locations
- 🇺🇸
Teva Investigational Site 12236, Memphis, Tennessee, United States
🇺🇸Teva Investigational Site 12246, Eustis, Florida, United States
🇺🇸Teva Investigational Site 12255, Ormond Beach, Florida, United States
Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 485
- Registration Number
- NCT02062463
- Locations
- 🇬🇧
Teva Investigational Site 34111, Colchester, United Kingdom
🇬🇧Teva Investigational Site 34105, Stanley, United Kingdom
🇬🇧Teva Investigational Site 34117, Stalham, United Kingdom
A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia
- Conditions
- Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT02044276
- Locations
- 🇮🇹
Teva Investigational Site 30059, Milano, Italy
🇩🇪Teva Investigational Site 32275, Koeln, Germany
🇩🇪Teva Investigational Site 32284, Aurich, Germany